Sign In
Buy BCYC
$4.20
-0.1000 (-2.33%)
At Close: Jun 03, 2026
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting
09:09pm, Wednesday, 13'th May 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Bicycle Therapeutics Announces Publication of BT5528 Mechanism of Action in AACR Journal Molecular Cancer Therapeutics
10:59am, Tuesday, 12'th May 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Growth Investors: Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
01:32pm, Friday, 08'th May 2020
Celebrations may be in order for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, with the analysts delivering a...
Bicycle Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
10:59am, Thursday, 07'th May 2020
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today repor
Bicycle Therapeutics to Present at the Bank of America 2020 Health Care Conference
10:59am, Wednesday, 06'th May 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today anno
Bicycle Therapeutics Announces First Patient Dosed in Phase I Dose Escalation of BT5528 in Combination with Nivolumab
10:59am, Tuesday, 05'th May 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Bicycle Therapeutics Appoints Zafar Qadir as General Counsel
10:59am, Thursday, 23'rd Apr 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
JPMorgan strategists to hold an analyst/industry conference call
03:13pm, Friday, 17'th Apr 2020
JPMorgan strategists to hold an analyst/industry conference call
State Street sees Q2 NII down 11% vs. Q1 excluding items STT
03:13pm, Friday, 17'th Apr 2020
State Street sees Q2 NII down 11% vs. Q1 excluding items STT
Las Vegas Sands mulls deals for existing resorts, Bloomberg reports LVS
03:13pm, Friday, 17'th Apr 2020
Las Vegas Sands mulls deals for existing resorts, Bloomberg reports LVS
Exact Sciences receives FDA EUAoapproval for COVID-19 test EXAS
03:12pm, Friday, 17'th Apr 2020
Exact Sciences receives FDA EUAoapproval for COVID-19 test EXAS
State Street sees 2020 management fees down 3%-5% STT
03:12pm, Friday, 17'th Apr 2020
State Street sees 2020 management fees down 3%-5% STT
Benchmark likes Regeneron in premarket analyst action
11:18am, Friday, 17'th Apr 2020
Axovant Gene Therapies (NASDAQ:AXGT) initiated with an Overweight rating and a $11 (209% upside) price target at Cantor Fitzgerald.Bicycle Therapeutics (NASDAQ:BCYC) initiated with a Buy rating and a
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Amag Pharmaceuticals (AMAG)
11:16am, Friday, 17'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicycle Therapeutics (BCYC) and Amag Pharmaceuticals (AMAG)
